Health Catalyst Full Year 2024 Earnings: EPS Misses Expectations

Simply Wall St

February 28, 2025

Health Catalyst (NASDAQ:HCAT) Full Year 2024 Results

Key Financial Results

Revenue: US$306.6m (up 3.6% from FY 2023).
Net loss: US$69.5m (loss narrowed by 41% from FY 2023).
US$1.16 loss per share (improved from US$2.09 loss in FY 2023).

revenue-and-expenses-breakdown — NasdaqGS:HCAT Revenue and Expenses Breakdown February 28th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Health Catalyst EPS Misses Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 11%.

The primary driver behind last 12 months revenue was the Technology segment contributing a total revenue of US$194.9m (64% of total revenue). Notably, cost of sales worth US$164.8m amounted to 54% of total revenue thereby underscoring the impact on earnings. The largest operating expense was Research & Development (R&D) costs, amounting to US$56.8m (27% of total expenses). Explore how HCAT's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 9.0% p.a. on average during the next 3 years, compared to a 9.6% growth forecast for the Healthcare Services industry in the US.

Performance of the American Healthcare Services industry.

The company's shares are down 19% from a week ago.

Risk Analysis

Don't forget that there may still be risks. For instance, we've identified 1 warning sign for Health Catalyst that you should be aware of.

Valuation is complex, but we're here to simplify it.

Discover if Health Catalyst might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.